A study found that administering a booster dose of Covaxin improves vaccination efficacy against Delta variant infection and provides protection against two Omicron variants of COVID-19.
The study published on Tuesday by ‘bioRxiv,’ an open-access preprint repository for the biological sciences, found that administering a Covaxin booster dosage improves vaccination efficacy against Delta variant infection and provides protection against Omicron variants BA.1.1 and BA.2. The study looked at immunity to SARS-CoV-2 acquired by spontaneous infection or vaccination. According to the study, vaccine efficacy varies depending on the type of sickness.
“Despite the comparable neutralising antibody response against the homologous vaccine strain in both the second dose and third dose immunised groups, significant reduction in lung disease severity was observed in the third dose immunised group post-Delta variant challenge, indicating the involvement of cell-mediated immune response also in protection,” the study continued.
“In the vaccine effectiveness study against the Omicron variants BA.1 and BA.2, the inoculated groups had lower virus shedding, lung viral load, and lung disease severity than the placebo groups. The current study demonstrates that administering a COVAXIN booster dosage improves vaccination efficacy against Delta variant infection and provides protection against Omicron variants BA.1.1 and BA.2 “It was finished.
The Covaxin vaccine, produced by the Indian Council of Medical Research (ICMR) in collaboration with Bharat BiotechInternational Limited (BBIL), shows an interim effectiveness of 81% in preventing Covid-19.
Covaxin is the first COVID-19 vaccine produced entirely in India. India began its countrywide immunisation campaign on January 16, 2021.
Follow Medically Speaking on Instagram